牛牛AI助理已提取核心訊息
Adial Pharmaceuticals, Inc. received a communication from the United States Securities and Exchange Commission (SEC) on January 19, 2024, regarding its Registration Statement on Form S-3, which was filed on January 12, 2024. The SEC informed the Chief Financial Officer, Joseph Truluck, that the agency has not reviewed and will not review the registration statement. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. Doris Stacey Gama was provided as a point of contact for any further questions.
Adial Pharmaceuticals, Inc. received a communication from the United States Securities and Exchange Commission (SEC) on January 19, 2024, regarding its Registration Statement on Form S-3, which was filed on January 12, 2024. The SEC informed the Chief Financial Officer, Joseph Truluck, that the agency has not reviewed and will not review the registration statement. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. Doris Stacey Gama was provided as a point of contact for any further questions.
Adial Pharmicals, Inc.於2024年1月19日收到美國證券交易委員會（SEC）關於其於2024年1月12日提交的S-3表格註冊聲明的來文。美國證券交易委員會告知首席財務官約瑟夫·特魯魯克，該機構尚未審查註冊聲明，也不會審查註冊聲明。美國證券交易委員會的信中還提到了與加快註冊程序的請求有關的第460和461條。此外，美國證券交易委員會提醒該公司及其管理層，無論美國證券交易委員會的審查程序如何，他們都有責任確保披露的準確性和充分性。如果有任何其他問題，多麗絲·斯泰西·伽瑪可以作爲聯繫人。
Adial Pharmicals, Inc.於2024年1月19日收到美國證券交易委員會（SEC）關於其於2024年1月12日提交的S-3表格註冊聲明的來文。美國證券交易委員會告知首席財務官約瑟夫·特魯魯克，該機構尚未審查註冊聲明，也不會審查註冊聲明。美國證券交易委員會的信中還提到了與加快註冊程序的請求有關的第460和461條。此外，美國證券交易委員會提醒該公司及其管理層，無論美國證券交易委員會的審查程序如何，他們都有責任確保披露的準確性和充分性。如果有任何其他問題，多麗絲·斯泰西·伽瑪可以作爲聯繫人。
有用
沒用